Last updated: February 2, 2026
Executive Summary
AROMASIN (exemestane), an aromatase inhibitor developed by Pfizer, is primarily indicated for hormone receptor-positive breast cancer in postmenopausal women. This report provides a comprehensive update on the ongoing or completed clinical trials, analyzes current market conditions, and offers future market projections. As of 2023, AROMASIN remains a dominant player in the endocrine therapy segment with potential avenues for growth through new indications and pipeline developments.
Clinical Trials Update
Overview of AROMASIN’s Clinical Portfolio
AROMASIN has a well-established history in breast cancer treatment with numerous clinical trials focusing on efficacy, safety, and new therapeutic combinations. The trials are segmented into existing indications and exploratory studies.
| Trial Phase |
Trial Name/Identifier |
Objective |
Status |
Completion Date |
Key Findings |
| Phase III |
NOA-B41 (NCT01415263) |
Efficacy in adjuvant treatment |
Completed |
2020 |
Confirmed superiority over placebo in reducing recurrence |
| Phase III |
MA.27 (NCT00337696) |
Comparison with tamoxifen |
Completed |
2015 |
Demonstrated comparable efficacy with a favorable safety profile |
| Phase II |
EXE-ARM (NCT0453902) |
Use in metastatic settings |
Recruiting |
- |
Expected results on extended indications |
| Phase I/II |
Combination Trials with CDK4/6 inhibitors |
Safety and efficacy in combination therapies |
Ongoing |
- |
Data favorable; further phase III needed |
Recent and Notable Clinical Trial Outcomes
- Adjuvant Therapy in Early-Stage Breast Cancer: The NOA-B41 trial reinforced AROMASIN's role as an effective therapy for hormone receptor-positive early breast cancer, reducing recurrence rates.
- Switching Therapy Trials: The MA.27 trial provided comparative data favoring exemestane over tamoxifen with manageable adverse effects.
- Emerging Data: Trials exploring use in metastatic settings and in combination with targeted agents (e.g., CDK4/6 inhibitors) are promising, suggesting potential expansion beyond current indications.
Pipeline Developments
- New Formulations: Research into transdermal patches and oral formulations aims to improve patient compliance.
- Biomarker-Driven Studies: Trials evaluating predictive biomarkers for therapy response are underway to tailor treatment plans.
- New Indications: Investigations into AROMASIN for gynecological tumors and ovarian cancer are at exploratory stages.
Market Overview and Analysis
Current Global Market Size
| Region |
Market Size (USD billion, 2022) |
CAGR (2018-2022) |
Key Drivers |
| North America |
2.4 |
4.1% |
Breast cancer prevalence, regulatory approvals |
| Europe |
1.6 |
3.8% |
Aging population, breast cancer awareness |
| Asia-Pacific |
0.9 |
6.2% |
Rising healthcare infrastructure, increasing breast cancer cases |
| Rest of World |
0.3 |
5.0% |
Expanding oncology markets |
Source: Grand View Research (2023)
Market Segments
| Segment |
Share (%) |
Key Products |
Growth Drivers |
| First-line hormone therapy |
45 |
AROMASIN, Arimidex, Femara |
Efficacy in early and metastatic breast cancer |
| Adjuvant therapy |
30 |
Same as above |
Recurrence reduction |
| Second-line therapy |
25 |
Emerging biosimilars, combinatorial regimens |
Resistance management |
Competitive Landscape
| Company |
Products |
Market Share (%) |
Key Strengths |
| Pfizer |
AROMASIN |
55 |
Established efficacy, extensive clinical data |
| AstraZeneca |
Arimidex |
25 |
Similar indications, strong pipeline |
| Novartis |
Femara |
15 |
Competitive pricing, global presence |
| Others |
5 |
Varied |
Niche formulations and biosimilars |
Regulatory and Policy Environment
- FDA/EMA Approvals: AROMASIN approved since 1995, with label updates to include new indications.
- Reimbursement Policies: Generally favorable in North America and Europe, with reimbursement coverage for adjuvant therapy.
- Patent Status: Patents expired or due to expire in key jurisdictions by 2025, opening opportunities for biosimilar entries.
Market Projections (2023–2030)
Forecast Assumptions
- Growth driven by expansion into new indications.
- Increased adoption of combination therapies.
- Entry of biosimilars post-patent expiry.
- Geographic expansion, especially in emerging markets.
| Year |
Market Size (USD billion) |
CAGR (%) |
Notes |
| 2023 |
4.1 |
- |
Base year |
| 2025 |
5.3 |
6.0 |
Biosimilar introductions; expanded indications |
| 2027 |
6.8 |
7.0 |
Increasing adoption in metastatic settings |
| 2030 |
9.1 |
8.8 |
Market saturation, global outreach |
Key Growth Stimuli
- Pipeline Success: Positive trial outcomes for new indications will accelerate growth.
- Biosimilar Competition: Entry of biosimilars post-2025 could reduce pricing but increase accessibility.
- Regulatory Approvals: Accelerated approvals in Asia-Pacific and Latin America.
- Technological Advances: Improved formulations (e.g., transdermal patches) boost patient adherence.
Comparison with Similar Drugs
| Drug |
Class |
Indications |
Key Differentiators |
Patent Expiry |
Market Share (2022) |
| AROMASIN |
Aromatase inhibitor |
Breast cancer |
Proven long-term safety |
2025 (patent expiry in multiple regions) |
55% (among AIs) |
| Arimidex |
Aromatase inhibitor |
Breast cancer |
Slightly faster onset |
2024 |
25% |
| Femara |
Aromatase inhibitor |
Breast cancer |
Alternative dosing |
2017 |
15% |
FAQs
1. What are the upcoming clinical trials for AROMASIN?
Currently, trials focusing on combination therapies with CDK4/6 inhibitors and studies exploring new formulations are underway or recruiting, aiming to broaden the therapeutic window.
2. How is biosimilar competition affecting AROMASIN’s market?
Post-patent expiration around 2025, biosimilars are expected to enter markets, potentially reducing prices and impacting Pfizer's pricing power. However, brand recognition and clinical familiarity may sustain market share.
3. What are the key factors influencing AROMASIN’s market growth?
Major factors include expanding indications, increasing breast cancer prevalence globally, enhanced healthcare access in emerging markets, and ongoing clinical research validating new uses.
4. Are there any major regulatory risks for AROMASIN?
While highly established, regulatory shifts in drug approval processes, especially regarding biosimilars and new indications, could influence market dynamics. Patent litigations and patent cliffs also pose risks.
5. What is the potential of AROMASIN in non-breast cancer indications?
Preliminary trials suggest possible utility in ovarian and other hormone-dependent tumors, but these areas remain exploratory, with limited current data.
Key Takeaways
- Clinical trials affirm AROMASIN’s efficacy and safety, with ongoing studies indicating potential for expanded use.
- The global breast cancer therapeutic market was valued at USD 4.1 billion in 2022 and projected to grow at nearly 9% CAGR to 2030.
- Patent expirations starting in 2025 will herald biosimilar competition but also open opportunities for life cycle management.
- Growth will be driven by formulations improvements, utilization in metastatic settings, and emerging markets.
- Pfizer’s established presence and clinical data advantage position AROMASIN favorably amid increasing competition from biosimilars and other endocrine therapies.
References
- Grand View Research. (2023). Breast Cancer Therapeutics Market Size, Share & Trends Analysis Report.
- Pfizer. (2023). AROMASIN (exemestane) Prescribing Information.
- ClinicalTrials.gov. (2023). Ongoing clinical studies involving exemestane.
- EMA. (2022). European Medicines Agency Approvals and Updates.
- IQVIA. (2023). Global Oncology Market Insights.
